According to the lawsuit, throughout the Class Period, defendants made false and misleading statements regarding Indivior’s business, operations, and prospects. Specifically, defendants:
- grossly overstated their ability to forecast the negative impact of certain legislation on the financial prospects of Indivior products, which forecasting ability was far less capable and effective than defendants had led investors and analysts to believe;
- overstated the financial prospects of SUBLOCADE (a monthly injection used to treat moderate to severe opioid use disorders), PERSERIS (an injection to treat schizophrenia in U.S. adults) and OPVEE (a nasal spray to reverse opioid overdoses on an emergency basis), and thus overstated the Company’s anticipated revenue and other metrics;
- knew or recklessly disregarded that because of the negative impact of certain legislation on the financial prospects of Indivior’s products, Indivior was unlikely to meet its own previously issued and repeatedly reaffirmed Fiscal Year 2024 net revenue guidance, including its Fiscal Year 2024 net revenue guidance for SUBLOCADE, PERSERIS and OPVEE;
- knew or recklessly disregarded that Indivior was at a significant risk of, and/or was likely to, cease all sales and marketing activities related to PERSERIS; and
- knew or recklessly disregarded that, as a result of the foregoing, Indivior’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
